Drug intelligence / Profile preview

SR-02

Development stage: Phase 2
Lead developer: Seraxis
Modality: Stem Cell Therapies → Cell Therapies
Administration: Implantation

Overview

SR-02 is an allogeneic cell therapy consisting of pancreatic endocrine cell clusters derived from a proprietary human stem cell line. Developed by Seraxis, it is designed as a replacement therapy for patients with Type 1 diabetes and insulin-requiring Type 2 diabetes. The therapy involves the implantation of these clusters into the omentum to restore endogenous insulin production and glycemic stability. In its current clinical application, SR-02 is administered alongside systemic immunosuppression to prevent immune rejection of the allogeneic cells. It is currently being evaluated in Phase 1/2 clinical trials for adults with unstable Type 1 diabetes who experience severe recurrent hypoglycemia.

Other names: Pancreatic Endocrine Cell ClustersReplacement Pancreatic Islets

Beyond the preview

Go deeper on SR-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-02.

Explore the full profile